Article

PHASE II TRIAL OF INTRAVENOUSLY ADMINISTERED AMD3100 (PLERIXAFOR) FOR STEM CELL MOBILIZATION IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION FOLLOWING A LENALIDOMIDE BASED INITIAL THERAPY

Biology of Blood and Marrow Transplantation (Impact Factor: 3.35). 02/2012; 18:S247-S247. DOI: 10.1016/j.bbmt.2011.12.129
0 Followers
 · 
89 Views